A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis

Trial summary:

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis

Receptor status / problem studied:


Inclusion criteria

  • Adults ≥18 years of age
  • Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by treating physician according to the World Health Organization (WHO) criteria
  • Palpable spleen measuring ≥5 cm below the LLCM or spleen volume of ≥450 cm3 by MRI or CT scan assessment
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
  • Adequate hematologic, hepatic, and renal functions

Exclusion criteria

  • Prior treatment with any BCR-ABL, phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), bromodomain and extraterminal domain (BET) or spleen tyrosine kinase (Syk) inhibitors
  • Cohorts 1 and 2 – Prior treatment with JAKi within 21 days of the Screening MRI/CT scan. Subjects in Cohort 3 must not have received JAKi
  • Prior splenectomy or splenic irradiation within 24 weeks prior to first dose of study treatment

View more trial information

Recruitment completed

Trial Title



Myeloproliferative disorders

Type of trial


Type of treatement




View all clinical trials


Become a patient